Xenetic Biosciences
XBIO
10 hedge funds and large institutions have $1.13M invested in Xenetic Biosciences in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
67% more funds holding
Funds holding: 6 → 10 (+4)
0% more ownership
Funds ownership: 0.03% → 0.04% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
20% less capital invested
Capital invested by funds: $1.41M → $1.13M (-$277K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$117K |
| 2 |
VF
Virtu Financial
New York
|
+$42.6K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$33.6K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$15.6K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$390 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$41K |
| 2 |
Morgan Stanley
New York
|
-$390 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Royal Bank of Canada
Toronto,
Ontario, Canada
| $917K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $102K | +$117K | +300 | New |
|
|
VF
3
Virtu Financial
New York
| $37K | +$42.6K | +109 | New |
|
|
PAM
4
Panagora Asset Management
Boston,
Massachusetts
| $31K | +$15.6K | +40 | +77% |
|
|
5
Acadian Asset Management
Boston,
Massachusetts
| $30K | +$33.6K | +86 | New |
|
|
6
Morgan Stanley
New York
| $9K | -$390 | -1 | -4% |
|
|
RE
7
RBC Europe
London,
United Kingdom
| $3.6K | – | – | – |
|
|
OIA
8
OneDigital Investment Advisors
Overland Park,
Kansas
| $1K | – | – | – |
|
|
9
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$41K | -83 | Closed |
|
|
10
Bank of America
Charlotte,
North Carolina
| – | +$390 | +1 | New |
|
11
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$390 | +1 | New |
|
XBIO Hedge Fund Activity: Q3 2018 in Review
10 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q3 2018, worth a combined $1.13M — down 20% from $1.41M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new XBIO positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $117K. The largest seller was Bank of Montreal, exiting entirely with an estimated $41K sold.
- 10 institutional investors held Xenetic Biosciences (XBIO) as of Q3 2018, up from 6 in Q2 2018.
- Funds reported $1.13M of Xenetic Biosciences stock for Q3 2018, down 20% quarter-over-quarter.
- 5 funds opened new Xenetic Biosciences positions in Q3 2018 and 1 closed out, a net change of +4 holders.
- The largest Xenetic Biosciences buyer in Q3 2018 was Vanguard Group, an estimated $117K added.
- The largest Xenetic Biosciences seller in Q3 2018 was Bank of Montreal, an estimated $41K sold.
Based on aggregated 13F filings for Q3 2018.